Business Description
NFL Biosciences SA
ISIN : FR0014003XT0
Compare
Compare
Traded in other countries / regions
ALNFL.France82F.Germany IPO Date
2021-07-05Description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 70.68 | |||||
| Equity-to-Asset | 0.46 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -112.5 | |||||
| 3-Year EPS without NRI Growth Rate | -108.9 | |||||
| 3-Year Book Growth Rate | 14 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.45 | |||||
| 9-Day RSI | 45.13 | |||||
| 14-Day RSI | 44.75 | |||||
| 6-1 Month Momentum % | -17.08 | |||||
| 12-1 Month Momentum % | 41.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | |||||
| Quick Ratio | 1.74 | |||||
| Cash Ratio | 1.38 | |||||
| Days Payable | 399.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 | |||||
| Shareholder Yield % | 0.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -156.2 | |||||
| ROA % | -48.78 | |||||
| ROIC % | -164.69 | |||||
| ROC (Joel Greenblatt) % | -5928.36 | |||||
| ROCE % | -174.79 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 1.41 | |||||
| PB Ratio | 7.55 | |||||
| Price-to-Tangible-Book | 8.16 | |||||
| EV-to-EBIT | -5.13 | |||||
| EV-to-EBITDA | -5.23 | |||||
| Price-to-Net-Current-Asset-Value | 8.55 | |||||
| Price-to-Net-Cash | 16.33 | |||||
| Earnings Yield (Greenblatt) % | -19.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NFL Biosciences SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.278 | ||
| Beta | 2.05 | ||
| Volatility % | 98.07 | ||
| 14-Day RSI | 44.75 | ||
| 14-Day ATR (€) | 0.139339 | ||
| 20-Day SMA (€) | 1.8295 | ||
| 12-1 Month Momentum % | 41.9 | ||
| 52-Week Range (€) | 1.33 - 3.28 | ||
| Shares Outstanding (Mil) | 9.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NFL Biosciences SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NFL Biosciences SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
NFL Biosciences SA Frequently Asked Questions
What is NFL Biosciences SA(XPAR:ALNFL)'s stock price today?
The current price of XPAR:ALNFL is €1.80. The 52 week high of XPAR:ALNFL is €3.28 and 52 week low is €1.33.
When is next earnings date of NFL Biosciences SA(XPAR:ALNFL)?
The next earnings date of NFL Biosciences SA(XPAR:ALNFL) is .
Does NFL Biosciences SA(XPAR:ALNFL) pay dividends? If so, how much?
NFL Biosciences SA(XPAR:ALNFL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers